Bayview Legacy LLC sells 40K Arteris shares

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported selling a total of 40,000 shares of Arteris common stock in two open-market transactions.

Rhea-AI Filing Summary

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported selling a total of 40,000 shares of Arteris common stock in two open-market transactions. On March 25, it sold 7,012 shares at a weighted average price of about $18.03 per share, followed by 32,988 shares on March 26 at a weighted average price of about $18.35 per share.

The sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. After these transactions, Bayview Legacy, LLC indirectly holds 9,189,071 Arteris common shares, so the sale represents a small portion of its overall position.

Insider Trade Summary 10b5-1

Net Seller: 40,000 shares

Net Sell 2 txns

Insider Bayview Legacy, LLC

Role 10% Owner

Sold 40,000 shs ($732K)

Type	Security	Shares	Price	Value
Sale	Common Stock	32,988	$18.3458	$605K
Sale	Common Stock	7,012	$18.0309	$126K

Holdings After Transaction: Common Stock — 9,189,071 shares (Indirect, See Footnote)

Footnotes (5)

1. F1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by K. Charles Janac, as the manager of Bayview Legacy, LLC, on March 5, 2025.
2. F2. K. Charles Janac, in his individual capacity, has separately filed a Form 4 on the date hereof reporting the same transaction given his beneficial ownership of the reported security through Bayview Legacy, LLC, which he controls as its manager.
3. F3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.08 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. K. Charles Janac is the manager of Bayview Legacy, LLC and as such is deemed to have voting and dispositive power over the shares beneficially owned by Bayview Legacy, LLC.
5. F5. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.70 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FAQ

What insider transaction did Bayview Legacy, LLC report for Arteris (AIP)?

Bayview Legacy, LLC reported selling 40,000 shares of Arteris common stock in two open-market transactions. The sales occurred on March 25 and March 26, 2026, and were disclosed on a Form 4 insider trading report for this significant shareholder.

How many Arteris (AIP) shares did Bayview Legacy, LLC sell and at what prices?

Bayview Legacy, LLC sold 7,012 Arteris common shares on March 25 and 32,988 shares on March 26, totaling 40,000 shares. The weighted average sale prices were about $18.03 and $18.35 per share, based on multiple trades within stated price ranges.

Was the Bayview Legacy, LLC sale of Arteris (AIP) shares under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan adopted on March 5, 2025. Such pre-arranged plans allow insiders to schedule trades in advance, helping separate routine liquidity moves from discretionary market-timing decisions.

How many Arteris (AIP) shares does Bayview Legacy, LLC hold after these sales?

After the reported transactions, Bayview Legacy, LLC indirectly holds 9,189,071 shares of Arteris common stock. This indicates the 40,000 shares sold represent a small fraction of its overall stake, leaving its remaining ownership position still very substantial.

Who controls the Arteris (AIP) shares held by Bayview Legacy, LLC?

The filing notes that K. Charles Janac is the manager of Bayview Legacy, LLC and is deemed to have voting and dispositive power over the shares it beneficially owns. He also separately filed a Form 4 reporting the same Arteris transactions through this entity.

What price ranges were involved in Bayview Legacy, LLC’s Arteris (AIP) share sales?

Footnotes explain that the March 25 sales were executed between $18.00 and $18.08 per share, while the March 26 sales occurred between $18.00 and $18.70. The reported prices on the form are weighted average sale prices across multiple individual trades on each day.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bayview Legacy, LLC

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CALIFORNIA 95008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/25/2026		S(1)(2)		7,012	D	$18.0309(3)	9,222,059	I	See Footnote(4)
Common Stock	03/26/2026		S(1)(2)		32,988	D	$18.3458(5)	9,189,071	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by K. Charles Janac, as the manager of Bayview Legacy, LLC, on March 5, 2025.

2. K. Charles Janac, in his individual capacity, has separately filed a Form 4 on the date hereof reporting the same transaction given his beneficial ownership of the reported security through Bayview Legacy, LLC, which he controls as its manager.

3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.08 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. K. Charles Janac is the manager of Bayview Legacy, LLC and as such is deemed to have voting and dispositive power over the shares beneficially owned by Bayview Legacy, LLC.

5. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.70 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	K. Charles Janac	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)